Celecoxib for the prevention of sporadic colorectal adenomas.
By M. Bertagnolli, C. Eagle, A. Zauber, M. Redston, S. Solomon, KyungMann Kim, Jie Tang, R. Rosenstein, J. Wittes, D. Corle and 18 more. New England Journal of Medicine, 2006
1,061 citations recorded by the source corpus.
Subfields: Oncology, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/94f40adca5bccbe5a382b9aca59640bcc6274cb2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pharmacology
In Psychiatry and Mental health
Citations in the corpus
- Cancer-related inflammation (2008, background): “In addition, COX2 inhibitors have been shown to prevent the recurrence of both sporadic adenomatous polyps and adenomas in people with a genetic predisposition to developing thes”
- The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer (2009, neutral): “Furthermore, three large double blind randomized controlled trials, including the Adenoma Prevention with Celecoxib (APC) trial (Bertagnolli et al., 2006), the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (Arber et al.”
- Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. (2014, neutral): “Subsequent studies to test the drug against placebo, therefore, may challenge the safety of the “safe” drug (e.g., celecoxib) (50).”
- The tumour microenvironment as a target for chemoprevention (2007, critical): “For example, recent findings indicate that although celecoxib is an effective agent for the prevention of colorectal adenomas, it cannot be routinely recommended for this indication at present because of potential cardiovascular event”